iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications

A Prospective Evaluation of the Second Generation iStent Inject in Open-Angle Glaucoma Subjects on Two Preoperative Topical Ocular Hypotensive Medications

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03478293

Enrollment

Registered

2018-03-27

Start date

2018-02-27

Completion date

2020-12-30

Last updated

2022-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open Angle Glaucoma (POAG)

Brief summary

The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.

Detailed description

Interventions

DEVICEiStent inject surgery

Micro-invasive glaucoma surgery (MIGS) to implant iStent inject

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Masking description

Single (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Diagnosed with primary open angle glaucoma (POAG) * Subject on two ocular hypotensive medications

Exclusion criteria

* Traumatic, uveitic, neovascular, or angle closure glaucoma * Fellow eye already enrolled

Design outcomes

Primary

Measure	Time frame	Description
IOP reduction at 12 and 24 months on same number or fewer medications	12 months and 24 months	IOP reduction at 12 and 24 months on same number or fewer medications

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026